Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

RATIONALE: Intravenous administration of the selective serotonin re-uptake inhibitor, citalopram (20 mg), is known to increase plasma prolactin (PRL) and cortisol in human subjects. This suggests that citalopram may be a useful tool to probe brain serotonin function. OBJECTIVE: To find out whether lower doses of intravenous citalopram would be sufficient to increase plasma prolactin and cortisol. METHODS: Eleven subjects were tested on three occasions in a double-blind, cross-over design receiving: (a) placebo, (b) citalopram 5 mg and (c) citalopram 10 mg infused intravenously over a 30-min period. A further six subjects received intravenous citalopram (10 mg) on two occasions receiving in addition the 5-HT2A2C receptor antagonist, cyproheptadine (4 mg orally) or placebo, 6 h before each infusion in a double-blind, randomised, cross-over design. Plasma PRL and cortisol levels were measured before and for 150 min after the infusion. RESULTS: Citalopram increased plasma PRL and cortisol in a dose-related manner. Cyproheptadine lowered baseline PRL and cortisol but did not attenuate the endocrine responses to citalopram. Citalopram infusions were well-tolerated. CONCLUSIONS: Low-dose citalopram has potential utility as a neuroendocrine challenge test. The endocrine responses to citalopram are probably not mediated predominantly by 5-HT2A/2C receptors.

Type

Journal article

Journal

Psychopharmacology (Berl)

Publication Date

05/2001

Volume

155

Pages

323 - 326

Keywords

Adult, Citalopram, Cross-Over Studies, Cyproheptadine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hydrocortisone, Male, Middle Aged, Neurosecretory Systems, Pilot Projects, Prolactin, Receptor, Serotonin, 5-HT2A, Receptors, Serotonin, Serotonin Antagonists, Serotonin Uptake Inhibitors